URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00392548

Enrollment

130

Registered

2006-10-26

Start date

2006-10-31

Completion date

2006-10-31

Last updated

2006-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Keywords

GBM, glioblastoma, urine, VEGF, radiation, Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.

Brief summary

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy. Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

Detailed description

Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy. * Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.) * Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.

Exclusion criteria

* Patient not able to receive 6000 cGy of radiation therapy.

Countries

Israel

Contacts

Primary ContactDeborah T Blumenthal, MD

deborahblumenthal@gmail.com011972524266304

Backup ContactLina Vizelman, BS

linav@tasmc.health.gov.il01197236977532

Outcome results